{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:08:29Z","timestamp":1790089709843,"version":"4.0.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010249","name":"Indiana University School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010249","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with locally advanced or metastatic sarcoma have a poor prognosis and limited efficacious treatment options. Phase 2 trials have demonstrated efficacy for the combination of ipilimumab and nivolumab in select sarcoma histologies, but real-world data is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-institution retrospective analysis, patients with metastatic or unresectable sarcoma treated with the combination of immune checkpoint inhibitors (ICIs) ipilimumab and nivolumab were assessed for response by iRECIST criteria and were correlated with clinical outcomes. The Kaplan\u2013Meier method was used for survival analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 2019 to 2024, 90 patients with advanced sarcoma were treated with combination ICI and were evaluable for outcomes. The observed objective response rate (ORR) was 16.7% with clinical benefit rate (CBR) of 30%. The best response was partial response (PR) in 14.4%, stable disease (SD) in 23.3%, and progressive disease (PD) in 62.2%. Median overall survival (OS) (95% confidence interval [CI] 14.4-NE months) and median progression-free survival (mPFS) (95% CI, 9.6-NE months) were not reached for patients achieving an objective response. OS was superior in patients who experienced immune-related adverse events (irAEs). Both mPFS and median overall survival were superior in patients with thyroid irAEs. Highest ORR were seen in angiosarcoma, malignant peripheral nerve sheath tumor, leiomyosarcoma, undifferentiated pleomorphic sarcoma, and chondrosarcoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Real-world analysis of combination ICI in a large cohort of heavily pretreated patients with advanced sarcomas demonstrates clinical benefit in a meaningful number of patients, including historically unresponsive histologies, though predictive factors remain elusive. The development of irAEs, specifically thyroid dysfunction, was associated with improved survival. Sustained responses were observed in patients who achieved an objective response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag348","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:20:50Z","timestamp":1788236450000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-world experience with ipilimumab in combination with nivolumab in advanced sarcoma: a retrospective analysis including ultra-rare sarcomas"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7338-7213","authenticated-orcid":false,"given":"Benjamin","family":"Snyder","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, Indiana University Melvin and Bren Simon Cancer Center , 535 Barnhill Dr , Indianapolis, IN 46202,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Wendorff","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Indiana University Melvin and Bren Simon Cancer Center , 535 Barnhill Dr , Indianapolis, IN 46202,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korbin","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Indiana University Melvin and Bren Simon Cancer Center , 535 Barnhill Dr , Indianapolis, IN 46202,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Blackwell","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Medical University of South Carolina, 171 Ashley Ave , Charleston, SC 46202,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Childress","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Indiana University Melvin and Bren Simon Cancer Center , 535 Barnhill Dr , Indianapolis, IN 46202,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Stethen","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Indiana University Melvin and Bren Simon Cancer Center , 535 Barnhill Dr , Indianapolis, IN 46202,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ani","family":"Toklu","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 350 W. 11th St,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Burney","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Indiana University Melvin and Bren Simon Cancer Center , 535 Barnhill Dr , Indianapolis, IN 46202,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Spargo","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Indiana University Melvin and Bren Simon Cancer Center , 535 Barnhill Dr , Indianapolis, IN 46202,","place":["United States"]},{"name":"Pharmacy Department, Roudebush VA Medical Center, 1481 W 10th St,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharathi","family":"Muthusamy","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Indiana University Melvin and Bren Simon Cancer Center , 535 Barnhill Dr , Indianapolis, IN 46202,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A","family":"Rushing","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Indiana University Melvin and Bren Simon Cancer Center , 535 Barnhill Dr , Indianapolis, IN 46202,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha A","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Indiana University Melvin and Bren Simon Cancer Center , 535 Barnhill Dr , Indianapolis, IN 46202,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2026092210522811700_oyag348-B1","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1158\/1078-0432.CCR-19-3416","article-title":"The immunosuppressive niche of soft-tissue sarcomas is sustained by tumor-associated macrophages and characterized by intratumoral tertiary lymphoid structures","volume":"26","author":"Chen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026092210522811700_oyag348-B2","doi-asserted-by":"publisher","first-page":"e1389366","DOI":"10.1080\/2162402X.2017.1389366","article-title":"PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue\u2014prognostic implications and rationale for immunotherapy","volume":"7","author":"Boxberg","year":"2018","journal-title":"Oncoimmunology"},{"key":"2026092210522811700_oyag348-B3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","article-title":"Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial","volume":"4","author":"Toulmonde","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026092210522811700_oyag348-B4","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026092210522811700_oyag348-B5","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/cas.70018","article-title":"Impact of tertiary lymphoid structure on prognosis and tumor microenvironment in undifferentiated pleomorphic sarcoma","volume":"116","author":"Sonoda","year":"2025","journal-title":"Cancer Sci"},{"key":"2026092210522811700_oyag348-B6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.32074\/1591-951X-213","article-title":"The 2020 WHO classification of soft tissue tumours: news and perspectives","volume":"113","author":"Sbaraglia","year":"2021","journal-title":"Pathologica"},{"key":"2026092210522811700_oyag348-B7","doi-asserted-by":"publisher","first-page":"7518","DOI":"10.3390\/ijms22147518","article-title":"Molecular determinants of soft tissue sarcoma immunity: targets for immune intervention","volume":"22","author":"Tazzari","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026092210522811700_oyag348-B8","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(24)01812-9","article-title":"Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial","volume":"404","author":"Mowery","year":"2024","journal-title":"Lancet"},{"key":"2026092210522811700_oyag348-B9","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D\u2019Angelo","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026092210522811700_oyag348-B10","doi-asserted-by":"publisher","first-page":"LBA11504","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA11504","article-title":"Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma","volume":"41(17_suppl)","author":"Tine","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026092210522811700_oyag348-B11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002990","article-title":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","volume":"9","author":"Wagner","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026092210522811700_oyag348-B12","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1200\/JCO-24-02524","article-title":"Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with relapsed\/refractory metastatic sarcomas","volume":"43","author":"Wilky","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026092210522811700_oyag348-B13","doi-asserted-by":"publisher","first-page":"11503","DOI":"10.1200\/JCO.2023.41.16_suppl.11503","article-title":"A multicenter phase II study of cabozantinib\u2009+\u2009nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (alliance A091902)","volume":"41","author":"Grilley-Olson","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026092210522811700_oyag348-B14","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D\u2019Angelo","year":"2024","journal-title":"Lancet"},{"key":"2026092210522811700_oyag348-B15","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.febslet.2013.11.030","article-title":"Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy","volume":"588","author":"Ahmed","year":"2014","journal-title":"FEBS Lett"},{"key":"2026092210522811700_oyag348-B16","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1002\/cncr.33618","article-title":"Ultra-rare sarcomas: a consensus paper from the connective tissue oncology society community of experts on the incidence threshold and the list of entities","volume":"127","author":"Stacchiotti","year":"2021","journal-title":"Cancer"},{"key":"2026092210522811700_oyag348-B17","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026092210522811700_oyag348-B18","doi-asserted-by":"publisher","first-page":"1209243","DOI":"10.3389\/fcell.2023.1209243","article-title":"Universal cutoff for tumor mutational burden in predicting the efficacy of anti-PD-(L)1 therapy for advanced cancers","volume":"11","author":"Mo","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"2026092210522811700_oyag348-B19","doi-asserted-by":"publisher","first-page":"17588359211058393","DOI":"10.1177\/17588359211058393","article-title":"Adverse events induced by nivolumab and ipilimumab combination regimens","volume":"14","author":"Somekawa","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"2026092210522811700_oyag348-B20","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.2217\/imt-2020-0155","article-title":"Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review","volume":"12","author":"Zhou","year":"2020","journal-title":"Immunotherapy"},{"key":"2026092210522811700_oyag348-B21","doi-asserted-by":"publisher","first-page":"e70052","DOI":"10.1002\/cncr.70052","article-title":"Clinical and biological factors associated with response to immune checkpoint inhibitors in advanced sarcomas: IMPRESARC, a French retrospective multicenter cohort study","volume":"131","author":"Fazel","year":"2025","journal-title":"Cancer"},{"key":"2026092210522811700_oyag348-B22","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1158\/1078-0432.CCR-24-3485","article-title":"Histologic and immunologic factors associated with response to immune checkpoint inhibitors in advanced sarcoma","volume":"31","author":"Lee","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026092210522811700_oyag348-B23","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S1470-2045(23)00282-6","article-title":"Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSe pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial","volume":"24","author":"Blay","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026092210522811700_oyag348-B24","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1007\/s00262-021-02876-w","article-title":"Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial","volume":"70","author":"Boye","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2026092210522811700_oyag348-B25","doi-asserted-by":"publisher","first-page":"e35628","DOI":"10.1002\/cncr.35628","article-title":"Nivolumab and sunitinib in patients with advanced bone sarcomas: a multicenter, single-arm, phase 2 trial","volume":"131","author":"Palmerini","year":"2025","journal-title":"Cancer"},{"key":"2026092210522811700_oyag348-B26","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1001\/jamaoncol.2020.3689","article-title":"Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1\/2 nonrandomized clinical trial","volume":"6","author":"Pollack","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026092210522811700_oyag348-B27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s43018-024-00726-z","article-title":"A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity\/truncal undifferentiated pleomorphic sarcoma","volume":"5","author":"Roland","year":"2024","journal-title":"Nat Cancer"},{"key":"2026092210522811700_oyag348-B28","doi-asserted-by":"publisher","first-page":"212","DOI":"10.36401\/JIPO-25-10","article-title":"Immunotherapy and targeted therapies in sarcoma: proposed synergy with combination treatment","volume":"8","author":"Watson","year":"2025","journal-title":"J Immunother Precis Oncol"},{"key":"2026092210522811700_oyag348-B29","doi-asserted-by":"publisher","first-page":"11500","DOI":"10.1200\/JCO.2023.41.16_suppl.11500","article-title":"Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): results of a phase II trial of the German interdisciplinary sarcoma group (GISG-15, NitraSarc)","volume":"41","author":"Reichardt","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026092210522811700_oyag348-B30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1200\/JCO.24.00358","article-title":"Phase Ib study for the combination of doxorubicin, dacarbazine, and nivolumab as the upfront treatment in patients with advanced leiomyosarcoma: a study by the Spanish sarcoma group (GEIS)","volume":"43","author":"Martin-Broto","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026092210522811700_oyag348-B31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41392-025-02278-9","article-title":"Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab","volume":"10","author":"Toulmonde","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"2026092210522811700_oyag348-B32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/0284186X.2023.2172688","article-title":"Immune-cell infiltration in high-grade soft tissue sarcomas; prognostic implications of tumor-associated macrophages and B-cells","volume":"62","author":"Nystrom","year":"2023","journal-title":"Acta Oncol"},{"key":"2026092210522811700_oyag348-B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005493","article-title":"Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR\/MSI-H metastatic colorectal cancer","volume":"11","author":"Nasca","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026092210522811700_oyag348-B34","doi-asserted-by":"publisher","first-page":"102164","DOI":"10.1016\/j.clgc.2024.102164","article-title":"Immune-related adverse events can predict progression-free and overall survival in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors","volume":"22","author":"Silberg","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"2026092210522811700_oyag348-B35","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s10147-023-02406-x","article-title":"Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis","volume":"28","author":"Washino","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"2026092210522811700_oyag348-B36","doi-asserted-by":"publisher","first-page":"e2352302","DOI":"10.1001\/jamanetworkopen.2023.52302","article-title":"Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors","volume":"7","author":"Cook","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026092210522811700_oyag348-B37","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/j.cllc.2020.01.003","article-title":"Association between early immune-related adverse events and clinical outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"21","author":"Hosoya","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"2026092210522811700_oyag348-B38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011545","article-title":"Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study","volume":"13","author":"Quandt","year":"2025","journal-title":"J Immunother Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag348\/70885999\/oyag348.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag348\/70885999\/oyag348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag348\/70885999\/oyag348.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:52:36Z","timestamp":1790088756000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag348\/8777192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag348","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,31]]},"article-number":"oyag348"}}